Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.76 |
| ▸ | DRD3 | P35462 | 7/20 | 0.76 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.76 |
| ▸ | HTR1A | P08908 | 6/20 | 0.76 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.76 |
| ▸ | HTR2A | P28223 | 5/20 | 0.76 |
| ▸ | HRH1 | P35367 | 4/20 | 0.76 |
| ▸ | HTR2B | P41595 | 4/20 | 0.76 |
| ▸ | DRD4 | P21917 | 4/20 | 0.76 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.76 |
| ▸ | USP2 | O75604 | 3/20 | 0.76 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.76 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.76 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.76 |
| ▸ | MEN1 | O00255 | 2/20 | 0.76 |
| ▸ | SLC22A2 | O15244 | 2/20 | 0.76 |
| ▸ | GMNN | O75496 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clopimozide SCHEMBL29710914 | 1.00 | DRD2 (0.76) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL11839760 | 0.97 | DRD2 (0.78) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL11841645 | 0.94 | DRD2 (0.72) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL1152828 | 0.92 | DRD2 (0.81) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| Clopimozide SCHEMBL11835033 | 0.90 | DRD2 (0.63) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL1152823 | 0.89 | DRD2 (0.76) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL11846888 | 0.89 | OPRM1 (0.76) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL1152218 | 0.89 | OPRM1 (0.76) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| Isopropyl Alcohol SCHEMBL11844720 | 0.88 | OPRM1 (0.70) | DRD2DRD3OPRM1HTR1ASLC6A4 | |
| SCHEMBL2615398 | 0.88 | DRD2 (0.75) | DRD2DRD3OPRM1HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2020-06-25 | — | — | US | claimed |
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION, INC. (US) | 2020-05-28 | — | — | US | claimed |
| EP-3615010-A1 | METHODS FOR TREATING DRAVET SYNDROME | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | claimed |
| EP-3615521-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | Cavion, Inc. (US) | 2020-03-04 | — | — | EP | claimed |
| EP-3423033-A1 | SELF-EMULSIFYING COMPOSITIONS OF CB2 RECEPTOR MODULATORS | Anavi-Goffer, Sharon (IL) | 2019-01-09 | — | — | EP | claimed |
| WO-2018200850-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CAVION, INC. (US) | 2018-11-01 | — | — | WO | claimed |
| WO-2018200844-A1 | METHODS FOR TREATING DRAVET SYNDROME | CAVION, INC. (US) | 2018-11-01 | — | — | WO | claimed |
| US-20180280357-A1 | METHODS FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | U.S. BANK NATIONAL ASSOCIATION | 2018-10-04 | — | — | US | claimed |
| EP-3364993-A1 | METHODS FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | Cavion, Inc. (US) | 2018-08-29 | — | — | EP | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-1044023-B1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | LUITPOLD PHARM INC (US) | 2005-05-25 | — | — | EP | claimed |
| US-6197764-B1 | COMPLEX WITH FATTY ACID; THERAPY FOR PSYCHOLOGICAL DISORDERS | PROTARGA, INC. | 2001-03-06 | — | — | US | claimed |
| EP-1044023-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | Protarga Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5955459-A | Fatty acid-antipsychotic compositions and uses thereof | NEUROMEDICA, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999026661-A1 | A COVALENT CONJUGATE OF CLOZAPINE WITH A FATTY ACID AND ITS USE FOR TREATING SCHIZOPHRENIA | PROTARGA INC. (US) | 1999-06-03 | — | — | WO | claimed |
| US-3989707-A | NEUROLEPTIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1976-11-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163943-A1 | METHODS FOR TREATING DRAVET SYNDROME | CACNA1G, CACNB2, CACNA1H | DRD2 991/4885DRD3 996/4885OPRM1 2638/4885 |
| US-20200197377-A1 | METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS | CACNA1G, CACNA1I, CACNA1H | DRD2 324/4885DRD3 436/4885OPRM1 2241/4885 |
| US-20180280357-A1 | METHODS FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS | CACNA1G, CACNA1I, CACNA1H | DRD2 593/4885DRD3 745/4885OPRM1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.